Potential Interactions between Exercise and Drug Therapy

被引:0
|
作者
Thomas L. Lenz
Nancy J. Lenz
Michele A. Faulkner
机构
[1] Creighton University Medical Center,Department of Pharmacy Practice, School of Pharmacy and Health Professions
[2] Madonna Rehabilitation Hospital,Physical Therapy Department
[3] Creighton University Medical Center,School of Pharmacy and Health Professions
来源
Sports Medicine | 2004年 / 34卷
关键词
Warfarin; Propranolol; Digoxin; Theophylline; Atenolol;
D O I
暂无
中图分类号
学科分类号
摘要
Certain physiological changes caused by aerobic exercise can alter the pharmacokinetics of some drugs. A systematic review of the pharmacokinetic changes that can affect drugs as a result of aerobic exercise is provided. Eleven commonly used drugs are reviewed for their potential interaction with exercising patients. Serum concentrations of two β-blocking agents, atenolol and propranolol, and one antibiotic, doxycycline, have shown to increase as a result of exercise. No pharmacokinetic changes have been found in exercising patients taking Carvedilol or verapamil. Patients who exercise after taking digoxin experience a decreased digoxin serum concentration with an increased skeletal muscle concentration. The clearance of theophylline has been shown to decrease resulting in an increase in plasma half-life during exercise. The risk of hypoglycaemia may increase when patients with diabetes mellitus inject insulin into a muscle just prior to exercising that muscle. Increasing physical activity in patients taking warfarin has been shown to decrease the international normalised ratio. Much is still unknown regarding the interactions that exist between exercise and drug therapy. More studies need to be completed in this area before definite conclusions are made and clinical relevance can be established. Clinicians should be aware that the potential for such interactions exists, especially for drugs with a narrow therapeutic range and in patients who participate in extreme sporting activities.
引用
收藏
页码:293 / 306
页数:13
相关论文
共 50 条
  • [1] Potential interactions between exercise and drug therapy
    Lenz, TL
    Lenz, NJ
    Faulkner, MA
    SPORTS MEDICINE, 2004, 34 (05) : 293 - 306
  • [2] The potential for drug interactions with statin therapy in Ireland
    Heerey A.
    Barry M.
    Ryan M.
    Kelly A.
    Irish Journal of Medical Science, 2000, 169 (3) : 176 - 179
  • [3] Interactions Between Antiretrovirals and Antineoplastic Drug Therapy
    Tony Antoniou
    Alice L. Tseng
    Clinical Pharmacokinetics, 2005, 44 : 111 - 145
  • [4] Interactions between antiretrovirals and antineoplastic drug therapy
    Antoniou, T
    Tseng, AL
    CLINICAL PHARMACOKINETICS, 2005, 44 (02) : 111 - 145
  • [5] Potential drug interactions in patients given antiretroviral therapy
    dos Santos, Wendel Mombaque
    Secoli, Silvia Regina
    de Mello Padoin, Stela Maris
    REVISTA LATINO-AMERICANA DE ENFERMAGEM, 2016, 24
  • [6] Clinical relevancy and risks of potential drug-drug interactions in intensive therapy
    Rodrigues, Aline Teotonio
    Stahlschmidt, Rebeca
    Granja, Silvia
    Eiras Falcao, Antonio Luis
    Moriel, Patricia
    Mazzola, Priscila Gava
    SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (04) : 366 - 370
  • [7] Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy
    Schulte, Benjamin
    Wuebbolding, Maximilian
    Marra, Fiona
    Port, Kerstin
    Manns, Michael P.
    Back, David
    Cornberg, Markus
    Stichtenoth, Dirk O.
    zu Siederdissen, Christoph Hoener
    Maasoumy, Benjamin
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (02):
  • [8] DRUG-EXERCISE INTERACTIONS
    LOWENTHAL, DT
    KENDRICK, ZV
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1985, 25 : 275 - 305
  • [9] EVALUATION OF POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN BEVIRIMAT AND RALTEGRAVIR IN VITRO
    Bullock, P. L.
    Han, M. S.
    Martin, D. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S82 - S82
  • [10] Drug interactions between antiepileptic drugs: elaboration of a tool to optimize drug therapy
    Dobremez, V.
    Maugras, C.
    Serra, A.
    Grosset-Janin, D.
    Giraud, P.
    Patin, S.
    Lotito, A.
    Berlioz, J.
    Pineau-Blondel, E.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 534 - 534